|
1
|
Vitamin E and donepezil for the treatment of mild cognitive impairment.
|
N Engl J Med
|
2005
|
12.04
|
|
2
|
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.
|
Alzheimers Dement
|
2009
|
10.21
|
|
3
|
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
|
N Engl J Med
|
2014
|
6.50
|
|
4
|
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium.
|
Alzheimers Dement
|
2008
|
6.39
|
|
5
|
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
|
JAMA
|
2003
|
6.34
|
|
6
|
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.
|
Lancet Neurol
|
2010
|
5.03
|
|
7
|
Developing a national strategy to prevent dementia: Leon Thal Symposium 2009.
|
Alzheimers Dement
|
2010
|
4.85
|
|
8
|
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease.
|
Neurobiol Aging
|
2009
|
4.36
|
|
9
|
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.
|
Alzheimers Dement
|
2011
|
3.05
|
|
10
|
A neuropsychological test battery for use in Alzheimer disease clinical trials.
|
Arch Neurol
|
2007
|
3.04
|
|
11
|
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.
|
Lancet Neurol
|
2012
|
2.75
|
|
12
|
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.
|
Arch Neurol
|
2012
|
2.61
|
|
13
|
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
|
Neurology
|
2012
|
2.26
|
|
14
|
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
|
Alzheimers Dement
|
2013
|
1.98
|
|
15
|
Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment.
|
Arch Neurol
|
2005
|
1.91
|
|
16
|
A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease.
|
Sleep
|
2003
|
1.58
|
|
17
|
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.
|
Arch Neurol
|
2007
|
1.57
|
|
18
|
Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI.
|
Neurobiol Aging
|
2007
|
1.57
|
|
19
|
Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals.
|
Neurobiol Aging
|
2012
|
1.43
|
|
20
|
Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis.
|
Neurodegener Dis
|
2008
|
1.39
|
|
21
|
Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders.
|
Curr Alzheimer Res
|
2009
|
1.34
|
|
22
|
A single ascending dose study of bapineuzumab in patients with Alzheimer disease.
|
Alzheimer Dis Assoc Disord
|
2010
|
1.29
|
|
23
|
The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials.
|
Alzheimers Dement
|
2012
|
1.16
|
|
24
|
Antioxidant strategies for Alzheimer's disease.
|
Proc Nutr Soc
|
2002
|
1.06
|
|
25
|
A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease.
|
Neurodegener Dis
|
2005
|
1.04
|
|
26
|
Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials.
|
Alzheimers Dement
|
2012
|
1.01
|
|
27
|
Laboratory investigations and treatment in frontotemporal dementia.
|
Ann Neurol
|
2003
|
0.90
|
|
28
|
Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing.
|
J Alzheimers Dis
|
2009
|
0.90
|
|
29
|
Hypothesis testing of a change point during cognitive decline among Alzheimer's disease patients.
|
J Alzheimers Dis
|
2003
|
0.86
|
|
30
|
Improving Alzheimer's disease phase II clinical trials.
|
Alzheimers Dement
|
2012
|
0.84
|
|
31
|
Weight loss in the elderly may be a sign of impending dementia.
|
Arch Neurol
|
2005
|
0.82
|
|
32
|
NSAIDs and hypertension.
|
Arch Intern Med
|
2003
|
0.81
|
|
33
|
Understanding the relative importance of preserving functional abilities in Alzheimer's disease in the United States and Germany.
|
Qual Life Res
|
2014
|
0.78
|
|
34
|
Estrogen levels do not correlate with improvement in cognition.
|
Arch Neurol
|
2003
|
0.78
|
|
35
|
Older Americans' risk-benefit preferences for modifying the course of Alzheimer disease.
|
Alzheimer Dis Assoc Disord
|
2009
|
0.76
|
|
36
|
Cognition in MCI and Alzheimer's disease: baseline data from a longitudinal study of the NTB.
|
Clin Neuropsychol
|
2014
|
0.75
|
|
37
|
Effectiveness of Florbetapir PET Imaging in Changing Patient Management.
|
Dement Geriatr Cogn Disord
|
2017
|
0.75
|